| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA616: Cladribine for treating relapsing–remitting multiple sclerosis |
|
Medicine details |
|
| Medicine name | cladribine (Mavenclad®) |
| Formulation | 10 mg tablet |
| Reference number | 440 |
| Indication | Treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features |
| Company | Merck Serono Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 26/04/2017 |
| NICE guidance | TA616: Cladribine for treating relapsing–remitting multiple sclerosis |